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flab gene was targeted by using multiplex qPCR accord-
ing to a previous described protocol (1). For quality con-
trol of qPCRs, we included positive and negative controls. 
Sequences of qPCR products were analyzed and compared 
with sequences available in GenBank.
B. miyamotoi was detected in 7 ticks: 2 (1.59%) of 
126 males, 2 (0.68%) of 296 females, and 3 (6.52%) of 
46 nymphs. A. phagocytophilum was detected in 16 ticks: 
1 (0.79%) of 126 males, 11 (3.72%) of 296 females, and 
4 (8.70%) of 46 nymphs. Candidatus N. mikurensis was 
detected in 25 ticks: 5 (3.97%) of 126 males, 18 (6.08%) of 
296 females, and 2 (4.35%) of 46 nymphs. Overall preva-
lences were 1.50% for B. miyamotoi, 3.42% for A. phago-
cytophilum, and 5.34% for Candidatus N. mikurensis. 
Prevalences of each pathogen in specific varied by locality 
(Table). No co-infections were detected.
We analyzed flab, msp2, and groEL gene sequences 
obtained by qPCR. These sequences showed 99%–100% 
identities with gene sequences of B. miyamotoi (GenBank 
accession no. KJ847050), A. phagocytophilum (accession 
no. KP164415), and Candidatus N. mikurensis (accession 
no. FJ966365).
In Romania, the density of Ix. ricinus ticks is high and 
their host diversity is extensive (7). However, data for ef-
fects of tickborne pathogens on public health are scarce in 
this country. In this study, we detected B. miyamotoi, A. 
phagocytophilum, and Candidatus N. mikurensis in questing 
Ix. ricinus ticks in Romania, which confirms the emerging 
trend of these pathogens in Europe. Because of the scarcity 
of information on human infections with these pathogens in 
Romania, serologic and molecular investigations and their 
implementation are needed for diagnosis, which might help 
in assessing the effect of these pathogens on public health.
This article was published in the framework of the European 
Social Fund, Human Resources Development Operational 
Program 2007−2013 (project POSDRU/159/1.5/S/136893) and 
EurNegVec COST Action TD1303.
This study supported by grant no. TE 298/2015 from the Execu-
tive Agency for Higher Education, Research, Development and 
Innovation Funding.
References
  1. Hansford KM, Fonville M, Jahfari S, Sprong H, Medlock JM.  
Borrelia miyamotoi in host-seeking Ixodes ricinus ticks in England. 
Epidemiol Infect. 2015;143:1079–87. http://dx.doi.org/10.1017/
S0950268814001691
  2. Jongejan F, Uilenberg G. The global importance of ticks.  
Parasitology. 2004;129(Suppl):S3–14. http://dx.doi.org/10.1017/
S0031182004005967
  3. Platonov AE, Karan LS, Kolyasnikova NM, Makhneva NA, 
Toporkova MG, Maleev VV, et al. Humans infected with relapsing 
fever spirochete Borrelia miyamotoi, Russia. Emerg Infect Dis. 
2011;17:1816–23. http://dx.doi.org/10.3201/eid1710.101474
  4. Crowder CD, Carolan HE, Rounds MA, Honig V, Mothes B, 
Haag H, et al. Prevalence of Borrelia miyamotoi in Ixodes ticks in 
Europe and the United States. Emerg Infect Dis. 2014;20:1678–82. 
http://dx.doi.org/10.3201/eid2010.131583
  5. Fonville M, Friesema IH, Hengeveld PD, Docters van Leeuwen A, 
Jahfari S, Harms MG, et al. Human exposure to tickborne relapsing 
fever spirochete Borrelia miyamotoi, the Netherlands. Emerg Infect 
Dis. 2014;20:1244–5. http://dx.doi.org/10.3201/eid2007.131525
  6. Kalmár Z, Cozma V., Sprong H, Jahfari S, D’Amico G,  
Mărcuțan DI, et al. Transstadial transmission of Borrelia turcica in 
Hyalomma aegyptium ticks. PLoS ONE. 2015;10:e0115520.  
http://dx.doi.org/10.1371/journal.pone.0115520
  7. Kalmár Z, Mihalca AD, Dumitrache MO, Gherman CM,  
Magdaş C, Mircean V, et al. Geographical distribution and 
prevalence of Borrelia burgdorferi genospecies in questing Ixodes 
ricinus from Romania: a countrywide study. Ticks Tick Borne Dis. 
2013;4:403–8. http://dx.doi.org/10.1016/j.ttbdis.2013.04.007
  8. Jahfari S, Fonville M, Hengeveld P, Reusken C, Scholte EJ,  
Takken W, et al. Prevalence of Neoehrlichia mikurensis in ticks  
and rodents from north-west Europe. Parasit Vectors. 2012;5:74.  
http://dx.doi.org/10.1186/1756-3305-5-74
  9. Matei IA, Kalmár Z, Magdaş C, Magdaş V, Toray H,  
Dumitrache MO, et al. Anaplasma phagocytophilum in questing  
Ixodes ricinus ticks from Romania. Ticks Tick Borne Dis. 
2015;6:408–13. http://dx.doi.org/10.1016/j.ttbdis.2015.03.010
10. Andersson M, Zaghdoudi-Allan N, Tamba P, Stefanache M,  
Chitimia L. Co-infection with ‘Candidatus Neoehrlichia  
mikurensis’ and Borrelia afzelii in an Ixodes ricinus tick that has 
bitten a human in Romania. Ticks Tick Borne Dis. 2014;5:706–8. 
http://dx.doi.org/10.1016/j.ttbdis.2014.05.013
Address for correspondence: Zsuzsa Kalmár, University of Agricultural 
Sciences and Veterinary Medicine, Calea Mănăștur 3–5, Cluj-Napoca 
400372, Romania; email: zsuzsa_kalmar@yahoo.com
Suspected Rabies in  
Humans and Animals,  
Laikipia County, Kenya
Mark Obonyo, James M. Akoko,  
Austine B. Orinde, Eric Osoro, Waqo Gufu Boru, 
Ian Njeru, Eric M. Fèvre
Author affiliations: Ministry of Agriculture, Livestock and Fisheries, 
Nairobi, Kenya (M. Obonyo, A.B. Orinde); Field Epidemiology and 
Laboratory Training Program, Nairobi (M. Obonyo, W.G. Boru);  
International Livestock Research Institute, Nairobi (J.M. Akoko, 
E.M. Fèvre); Kenya Zoonotic Disease Unit, Nairobi (A.B. Orinde, 
E. Osoro); Ministry of Health, Kenya (W.G. Boru, I. Njeru);  
University of Liverpool Institute of Infection and Global Health, 
Liverpool, UK (E.M. Fèvre)
DOI: http://dx.doi.org/10.3201/eid2203.151118
To the Editor: Dog bites are a serious public health 
problem because of the associated risk for rabies virus ex-
posure in countries to which the virus is endemic (1,2). 
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Human rabies can be prevented by administration of post-
exposure prophylaxis (PEP). However, PEP rabies vac-
cine may be unavailable or prohibitively expensive (3). 
Delay in or failure to receive PEP after possible rabies 
virus exposure contributes to increased incidence of hu-
man rabies deaths (3).
We performed a retrospective investigation of animal 
bites and postbite treatment in Laikipia North sub-county, 
Kenya, during January 2013–February 2014. Laikipia 
North is 1 of 3 sub-counties in Laikipia County and has a 
population of 32,726 (4). Our investigation was instigated 
by 3 suspected human rabies deaths that were informally 
reported to the Kenya Government Zoonotic Disease Unit 
(ZDU) during early 2014. We reviewed animal bite records 
from sub-county health facilities and veterinary offices and 
administered a structured household questionnaire to de-
termine outcomes, knowledge of rabies, bite management, 
healthcare-seeking behavior, and economic costs. This 
public health response was government coordinated and 
approved; no personal identifiers were retained.
During January 1, 2013–February 10, 2014, a total of 
106 bites were recorded by 6 government-run health fa-
cilities in Laikipia North. Median reported bite incidence 
per month was 24 bites/100,000 persons (range 6–45 
bites/100,000 persons). The median age of bite victims 
was 13 years (range 1–81 years); 61 (58%) bites occurred 
in males. Of all bites recorded, 94 (88%) were by dogs, 8 
(8%) by scorpions, and 4 (4%) by humans.
The deaths of 3 humans reported to the ZDU occurred 
in November and December 2013. To assess whether these 
cases were part of an exposure cluster, we followed up on 
bite cases during November 1–December 31, 2013. During 
this period, 17 additional animal bite cases were recorded. 
Of these 20 bite cases, we successfully traced the house-
holds of 11 (55%) case-patients, including 2 of the 3 who 
died from rabies. Bites were predominantly received from 
owned pets (82%), and most bites (82%) were reported to 
be unprovoked. All bites were inflicted on extremities, and 
almost all (91%) were single-bite injuries (Table 1).
Of 11 animals that bit case-patients, 7 had unknown his-
tories of rabies vaccination and 4 were not vaccinated (Table 
1). Four of the 11 animals were suspected to be rabid, in-
cluding 1 cat and 3 dogs. All the suspected rabid animals 
were reported to exhibit aggressive or abnormal behavior, 
drooling or salivation, vocalization, and roaming tendencies 
(5; online Technical Appendix Table 1, http://wwwnc.cdc.
gov/EID/article/22/3/15-1118-Techapp1.pdf). Three of the 
animals reportedly died; status was unknown for 1.
Of the 11 traced bite case-patients, 9 washed their 
wound before going to a healthcare facility and 8 were pre-
scribed PEP. The median time from bite to reporting to a 
health facility was 1 day (range 0–3 days). Four respondents 
delayed in starting PEP: 3 after 3 days, and 1 after 2 days. 
Reasons given for delay included the high cost of PEP by 3 
(including 1 who died); a health facility being too far away 
by 1, who died; and vaccine unavailable at nearest health fa-
cility by 2, 1 of whom died. Of 8 respondents who received 
PEP, 7 traveled >10 km to reach the nearest health facility. 
PEP availability was inconsistent at the sub-county hospi-
tal and local dispensaries; 6 of 8 respondents seeking PEP 
visited multiple facilities to receive PEP, including a county 
referral facility that was >100 km away. The World Health 
Organization’s 5-dose PEP regimen is recommended in Ke-
nya (1). However, only 3 case-patients were prescribed and 





Table. Responses to questionnaire interview of 11 animal bite 
victims assessed for rabies, Laikipia County, Kenya, 2014* 
Variables/categories No. (%) case-patients 
Time of bite  
 Evening 6 (55) 
 Morning 4 (36) 
 Afternoon 1 (9) 
Part of body bitten  
 Legs 8 (73) 
 Arms 3 (27) 
Circumstances of bite  
 Unprovoked 9 (82) 
 Animal provoked 2 (18) 
Type of animal  
 Dog 10 (91) 
 Cat 1 (9) 
Ownership of biting animal  
 Owned 9 (82) 
 Stray 2 (18) 
Rabies vaccination history of biting 
animal 
 
 Unknown 7 (64) 
 Not vaccinated 4 (36) 
Outcome of biting animal  
 Alive and normal 7 (64) 
 Deceased 4 (36) 
Wound washed after bite  
 Yes 9 (82) 
 No 2 (18) 
Treatment at healthcare facility  
 Anti-tetanus 9 (82) 
 PEP rabies vaccination 8 (72) 
 Pain killers 5 (46) 
Distance from nearest PEP facility, km  
 >10 7 (64) 
 5–10 3 (27) 
 0–5 1 (9) 
Source of PEP  
 Government facility 5 (63) 
 Chemist 2 (25) 
 Private hospital 1 (13) 
Costs of PEP, US$†  
 No. doses of PEP administered 23 
 Cost categories Average (range) 
  Cost/dose of PEP 8 (2–15) 
  Total cost of PEP doses 23 (8–50) 
  Direct medical cost 65 (2–500) 
  Indirect medical cost 34 (4–100) 
 Average cost for obtaining 1 dose of 
PEP 
45 (8–120) 
*PEP, postexposure prophylaxis. 
†Average annual exchange rate during 2013 was 1 Kenya 
shilling/$0.011586 US. 
 
received 5 doses. Five respondents were prescribed 3, 4, or 
6 doses (online Technical Appendix Table 2). This finding 
indicates large inconsistencies in the PEP prescribing prac-
tices in this region of Kenya, a pattern that is similar in other 
parts of East Africa (6).
Respondents bore all medical costs without subsidy. 
Direct medical costs were ≈$2 $500 (US) per bite victim, 
and indirect medical costs were ≈$4 $100. The average 
cost of obtaining a single dose of PEP ranged from $8 to 
$120 (Table; online Technical Appendix Table 2).
All respondents had heard of rabies. Nine (82%) knew 
it was transmitted to humans through a bite from a rabid 
dog, and 4 (36%) knew that rabies among dogs could be 
prevented through vaccination.
During 2014, at least 3 suspected human rabies deaths 
and 4 domestic animal deaths were associated with this 
cluster. Postbite care, including PEP, is a heavy economic 
burden on this community, moreso because rabies vaccine 
is not always locally accessible. Dog vaccination rates are 
low in this region and rabies in suspected animals is rarely 
definitively diagnosed, increasing risks for human rabies 
virus exposures and the economic burden of PEP admin-
istration. We recommend implementation of regular and 
comprehensive mass dog vaccination campaigns, in line 
with Kenya’s National Rabies Elimination Strategy (7), 
and further detailed studies on the epidemiology of rabies 
in this ecosystem, which supports human, wildlife, and do-
mestic dog populations.
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To the Editor: In October 2012, a 35-year-old man 
with clinical category C HIV infection was admitted to the 
intensive care unit at the University of Duisburg–Essen, Es-
sen, Germany. The man had severe respiratory distress syn-
drome with septic shock, and he was infected with hepatitis 
B and C viruses and Epstein-Barr virus. Standard infection-
control procedures were followed: the patient was placed in 
a single room; healthcare providers wore personal protec-
tive equipment (gown, face shield, mask, and gloves); and 
a closed system was used for endotracheal suctioning. 
Physical examination of the patient revealed multiple 
skin lesions on his right forearm and right leg. In the following 
days, more skin lesions appeared on his abdomen and head. 
The skin lesions were inflamed macules with central livid, 
hemorrhagic ulceration (1–2 cm in diameter) and raised edges. 
Kaposi sarcoma was suspected initially, but on hospital day 
5, a skin biopsy showed large intracellular eosinophilic inclu-
sion bodies pathognomonic for infection with cowpox virus 
(family Poxviridae, genus Orthopoxvirus). To confirm the di-
agnosis of cowpox virus infection, we conducted biopsies of 3 
skin lesions on hospital day 7. Despite antimicrobial drug and 
supportive therapy, the patient died that day from septic shock. 
The 3 biopsy samples obtained on hospital day 7 were 
cultured on African green monkey kidney (MA104) cells, 
and within 2 days, many plaques were observed. DNA ex-
tracted from homogenates and virus isolated from the bi-
opsy material were tested by orthopoxvirus real-time PCR 
(1); results were positive for all 6 samples. We confirmed 
the presence of cowpox virus DNA in all samples by se-
quencing the hemagglutinin gene.
Serum obtained from the patient on day 2 after admis-
sion, when the first lesions were noted, was also positive for 
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